We are a life sciences company focused on the discovery and commercialisation of novel epigenetic biomarkers.

We utilise EpiSwitch™, an award winning, patented and clinically validated discovery system developed by our AIM listed shareholder Oxford Biodynamics Plc

Our unique application of EpiSwitch™ to non-disease state problems aims to develop biomarkers that enable the non-pharmaceutical enhancement of health, wellness and performance in humans and animals.